Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.47% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INWK
2576
DELISTED
InnerWorkings, Inc.
INWK
| $1.12M | ﹤0.01% |
203,600
+84,900
| +72% | +$411K |
|
2577
Vanguard Morningstar Mid-Cap Value ETF
VOE
$23.7B
| $1.12M | ﹤0.01% |
9,400
+4,800
| +104% | +$553K |
|
|
SPRT
2578
DELISTED
support.com, Inc.
SPRT
| $1.12M | ﹤0.01% |
1,026,536
| – | – |
|
|
ADMS
2579
DELISTED
Adamas Pharmaceuticals
ADMS
| $1.11M | ﹤0.01% |
292,780
+169,145
| +137% | +$810K |
|
2580
iShares MSCI Australia ETF
EWA
$1.39B
| $1.11M | ﹤0.01% |
49,000
+19,400
| +66% | +$437K |
|
2581
Vanguard Morningstar Large-Cap ETF
VV
$52.4B
| $1.11M | ﹤0.01% |
+7,500
| New | +$1.06M |
|
|
SGMA
2582
DELISTED
Sigmatron International
SGMA
| $1.1M | ﹤0.01% |
272,928
+5,538
| +2% | +$23.4K |
|
2583
Innodata
INOD
$2.05B
| $1.1M | ﹤0.01% |
963,153
+20,600
| +2% | +$26.3K |
|
2584
State Street SPDR Bloomberg Emerging Markets Local Bond ETF
EBND
$2.26B
| $1.09M | ﹤0.01% |
39,227
+29,368
| +298% | +$807K |
|
2585
BioXcel Therapeutics
BTAI
$24.9M
| $1.09M | ﹤0.01% |
4,681
-175
| -4% | -$17.6K |
|
2586
Prothena Corp
PRTA
$425M
| $1.09M | ﹤0.01% |
69,100
+24,100
| +54% | +$258K |
|
|
SOL
2587
DELISTED
Emeren Group
SOL
| $1.09M | ﹤0.01% |
772,442
-6,409
| -0.8% | -$9.52K |
|
2588
iShares Core Moderate Allocation ETF
AOM
$1.75B
| $1.09M | ﹤0.01% |
27,163
+16,063
| +145% | +$636K |
|
2589
Schwab US Aggregate Bond ETF
SCHZ
$10.5B
| $1.08M | ﹤0.01% |
40,356
+16,756
| +71% | +$449K |
|
2590
Pluri
PLUR
$16.7M
| $1.08M | ﹤0.01% |
34,177
+10,898
| +47% | +$312K |
|
2591
Tenet Healthcare
THC
$20.5B
| $1.07M | ﹤0.01% |
28,275
-16,800
| -37% | -$503K |
|
2592
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.81B
| $1.07M | ﹤0.01% |
10,600
+1,600
| +18% | +$161K |
|
2593
Pure Cycle
PCYO
$253M
| $1.07M | ﹤0.01% |
85,200
-9,792
| -10% | -$115K |
|
|
PSB
2594
DELISTED
PS Business Parks, Inc.
PSB
| $1.07M | ﹤0.01% |
6,500
+1,088
| +20% | +$191K |
|
2595
Cannae Holdings
CNNE
$639M
| $1.07M | ﹤0.01% |
28,801
-145,999
| -84% | -$4.8M |
|
2596
Security National Financial
SNFCA
$244M
| $1.07M | ﹤0.01% |
263,761
+24,673
| +10% | +$89.9K |
|
|
ALLK
2597
DELISTED
Allakos
ALLK
| $1.07M | ﹤0.01% |
11,200
-151,500
| -93% | -$13.3M |
|
|
RYZ
2598
Ryerson Holding Corp
RYZ
$1.44B
| $1.07M | ﹤0.01% |
+90,200
| New | +$891K |
|
|
RBCN
2599
DELISTED
Rubicon Technology, Inc.
RBCN
| $1.07M | ﹤0.01% |
128,104
+2,900
| +2% | +$24.5K |
|
2600
Linde
LIN
$221B
| $1.06M | ﹤0.01% |
5,000
-173,800
| -97% | -$35M |
|
Similar funds
Renaissance Technologies's Q4 2019 Portfolio in Review
As of Q4 2019, Renaissance Technologies held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Renaissance Technologies's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Renaissance Technologies added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Renaissance Technologies's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Renaissance Technologies fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Renaissance Technologies's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Renaissance Technologies opened 518 new positions and closed 443 in Q4 2019.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.